Neurocrine's Vykat XR Faces Clinician Alert Over Post-Marketing Safety Reports
-3.37% to $156.49 from $161.94
What moved NBIX
- A coalition of physicians and Prader-Willi syndrome experts issued a joint clinician alert flagging post-marketing safety data on Neurocrine’s Vykat XR, including seven patient deaths and more than 100 reports of serious adverse events since its March 2025 approval.
- The groups stopped short of asserting the drug caused the reported outcomes, noting that the reports do not establish a causal relationship.
- Vykat XR’s existing label already lists hyperglycemia, including diabetic ketoacidosis, and severe fluid-overload-related edema among reported adverse reactions.
Sources: STAT News · Investing.com